Amedica Announces Patent Grant for Silicon Nitride and Other Ceramic Materials
March 30 2018 - 9:00AM
Amedica Corporation (Nasdaq:AMDA), an innovative biomaterial
company which develops and manufactures silicon nitride as a
platform for biomedical applications, is pleased to announce the
issuance of a key material and process patent. US patent
9,925,295 was issued to Amedica March 27, 2018, covering “Ceramic
and/or glass materials and related methods.” The patent covers
various methods for improving the antibacterial, osteoconductive,
and osteoinductive characteristics of silicon nitride and other
ceramic materials, particularly to make them more suitable for use
in manufacturing a variety of biomedical implants. Amedica
now has 59 US patents and 6 foreign patents.
“This patent reflects the scientific inquiry and
accomplishments in which Amedica has invested heavily during the
past few years. Other biomaterials usually require surface
textural engineering to make them suitable for applications such as
spinal fusion. Silicon nitride is unique in having a favorable
nanostructure in the “as-fired” state already. Therefore, our
focus has been to move beyond surface topography toward engineering
the precise surface chemistry of silicon nitride through thermal,
chemical, and/or mechanical treatments to achieve a broad-based
material platform that has applications throughout the biomedical
space. The innovative strength of this patent has attracted
several potential developing partnerships with other companies,
both in spine and outside. From an intellectual property
standpoint, this patent alone contributes to the lasting and
refreshed value in Amedica, specifically our scientific knowledge
and our ability to modify and control the material toward specific,
desired product applications.” said Dr. Sonny Bal, CEO and Chairman
at Amedica.
About Amedica
CorporationAmedica is focused on the development and
application of medical-grade silicon nitride ceramics. Amedica
markets spinal fusion products and is developing a new generation
of wear- and corrosion-resistant implant components for hip and
knee arthroplasty. The Company manufactures its products in its ISO
13485 certified manufacturing facility. Amedica's spine products
are FDA-cleared, CE-marked, and are currently marketed in the U.S.
and select markets in Europe and South America through its
distributor network and its OEM partnerships.
For more information on Amedica
or its silicon nitride material platform, please
visit www.amedica.com.
Forward-Looking Statements
This press release contains statements that
constitute forward-looking statements within the meaning of the
Securities Act of 1933 and the Securities Exchange Act of 1934, as
amended by the Private Securities Litigation Reform Act of 1995.
These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ
materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties. For example, there can be no assurance that this
patent will attract several potential developing partnerships with
other companies, both in spine and outside. Other factors
that could cause actual results to differ materially from those
contemplated within this press release can also be found in
Amedica's Risk Factors disclosure in its Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 29, 2018, and in Amedica's other filings with the SEC.
Forward-looking statements contained in this press release speak
only as of the date of this press release. We undertake no
obligation to update any forward-looking statements as a result of
new information, events or circumstances or other factors arising
or coming to our attention after the date hereof.
Contact:
Amedica IR
801-839-3502
IR@amedica.com
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Sep 2024 to Oct 2024
AMEDICA CORP (NASDAQ:AMDA)
Historical Stock Chart
From Oct 2023 to Oct 2024